Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin embonate
- Development stage
- Preclinical
- Lead developer
- University of Milano-Bicocca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Metformin embonate is a salt form of the biguanide metformin, specifically developed by the Università degli Studi di Milano-Bicocca for the treatment of IDH-wildtype glioblastoma. Unlike the standard hydrochloride salt, the embonate (pamoate) salt is characterized by low solubility, which facilitates its formulation into nanocrystals or other delivery systems designed to enhance therapeutic efficacy in the brain. Its mechanism of action involves the inhibition of mitochondrial complex I and the subsequent activation of AMP-activated protein kinase (AMPK), leading to the disruption of cancer cell metabolism and the inhibition of glioblastoma stem cell proliferation. This repositioning strategy aims to exploit the metabolic vulnerabilities of aggressive brain tumors.
- Other names
- metformin pamoatemetformin 4,4'-methylenebis(3-hydroxy-2-naphthoate)
02
Targets
GPD2 (Glycerol-3-phosphate dehydrogenase 2)AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on metformin embonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin embonate.